Work

Iclaprim, a Dihydrofolate Reductase Inhibitor Antibiotic in Phase III of Clinical Development: A Review of its Pharmacology, Microbiology and Clinical Efficacy and Safety

Year: 2018

Type: article

Source: Future Microbiology

DOI: 10.2217/fmb-2018-0061

Authors: David B Huang, Matthew Dryden

Institutions: Rutgers New Jersey Medical School, Hampshire Hospitals NHS Foundation Trust

Language: English

Topic: Antimicrobial Resistance in Staphylococcus

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2799714015

FWCI: 0.945

Cites: 22

Cited by: 20

Related to: 10